CN-121971449-A - Application of amaranth in preparation of antifungal medicines

Abstract

The invention relates to the technical field of biological medicines, in particular to application of amaranth in preparation of antifungal medicines. According to the invention, trace broth dilution method, dynamic time-sterilization curve, hypha growth and large wax moth animal test prove that the amaranth amine has remarkable antibacterial activity on the drug-resistant candida albicans with high expression of Cdr1 and Cdr2 genes, so that the amaranth amine can be used for preparing antifungal products.

Inventors

• TAN DONGMEI
• ZHANG AIJUAN
• Zhou Bingni
• DUAN XIMENG
• LIU YUE
• LI XIUYUN

Assignees

• 山东省妇幼保健院

Dates

Publication Date

20260505

Application Date

20260303

Claims (10)

1. 1. The application of laoguanamine in preparing antifungal products.
2. 2. The use of claim 1, wherein the product comprises pharmaceuticals and commodity products.
3. 3. The use of claim 2, wherein the commodity is a mouthwash or vaginal lotion.
4. 4. The use according to claim 1, wherein the fungus is candida albicans of the drug-resistant type with high expression of the Cdr1 and Cdr2 genes.
5. 5. An antifungal drug, which is characterized in that, including amantadine.
6. 6. The antifungal agent of claim 5 wherein the fungus is a drug-resistant candida albicans with high expression of the Cdr1 and Cdr2 genes.
7. 7. The antifungal agent of claim 5 wherein the agent further comprises a pharmaceutically acceptable carrier, excipient, and diluent.
8. 8. The antifungal agent of claim 7 wherein the carrier, excipient and diluent comprises, but is not limited to lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylparaben, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
9. 9. The antifungal agent of claim 5 wherein the agent is in the form of a suspension, emulsion, granule, spray, injection, transdermal absorbent, a dosage form suitable for transfection, a tablet, powder, granule, or capsule.
10. 10. A pharmaceutical composition comprising an antifungal agent according to any one of claims 5 to 9.

Description

Application of amaranth in preparation of antifungal medicines Technical Field The invention relates to the technical field of biological medicines, in particular to application of amaranth in preparation of antifungal medicines. Background The disclosure of this background section is only intended to increase the understanding of the general background of the invention and is not necessarily to be construed as an admission or any form of suggestion that this information forms the prior art already known to those of ordinary skill in the art. Fungal infections, particularly invasive fungal infections, continue to pose a serious threat to human health. Patients receiving organ transplantation, hematopoietic stem cell transplantation, cancer chemotherapy, intravenous catheterization, etc. or HIV infection can cause reduced immunity, resulting in high morbidity and mortality from invasive fungal infections. Among them, candida albicans, which is the most common clinical conditional pathogenic fungus, has become an important pathogen threatening the life health of immunocompromised people. When the immunity of the human body is reduced or the flora is deregulated, candida albicans can cause infection, such as thrush, pneumonia, enteritis, bronchitis, pyelonephritis, meningitis, endocarditis and the like. The azole medicine has the advantages of small adverse effect, high bioavailability and the like, and becomes the first choice medicine for preventing and treating candida albicans, however, the drug resistance of the azole medicine is very common due to the excessive use of the azole medicine, and the treatment effect of the azole medicine is seriously influenced. The high expression of the efflux pump is one of the core mechanisms for mediating the multi-drug resistance of candida albicans, wherein the ABC transporter Cdr1, cdr2 and the MFS transporter Mdr1 are the efflux pumps for mediating the drug resistance of candida albicans to azole drugs, and belong to ABC and MFS families respectively. Mdr1 is driven by proton gradient, and is mainly used for discharging azole drugs such as fluconazole and the like, while Cdr1 and Cdr2 are powered by ATP hydrolysis, and can also be used for discharging various azole drugs, so that multidrug resistance is caused. Because of the broad substrate spectrum of drug resistance mediated by the efflux pump, most of the existing anti-candida albicans drugs are difficult to escape from the effect of the efflux pump, and the development of specific inhibitors aiming at the mechanism is slow, so that the problem of 'no drug use' is often caused when the drug resistance candida albicans is expressed in high expression on the efflux pump clinically. Therefore, the development of novel antifungal drugs has become an urgent need for clinical urgent solutions. Disclosure of Invention In order to overcome the problems, the invention provides application of the amaranth in preparing antifungal medicines. In order to achieve the technical purpose, the invention adopts the following technical scheme: in a first aspect of the invention, there is provided the use of laoguanamine in the preparation of an antifungal product. In one or more embodiments, the products include pharmaceuticals and commodity products. Preferably, the commodity is a mouthwash or vaginal lotion. In one or more embodiments, the fungus is drug-resistant candida albicans with high expression of the Cdr1 and Cdr2 genes. In a second aspect of the invention, there is provided an antifungal agent comprising amantadine. In one or more embodiments, the fungus is drug-resistant candida albicans with high expression of the Cdr1 and Cdr2 genes. In one or more embodiments, the medicament further includes pharmaceutically acceptable carriers, excipients, diluents, and the like. The non-pharmaceutically active ingredients, such as carriers, excipients and diluents, which may be included, are well known in the art and can be determined by one of ordinary skill in the art to meet clinical criteria. Preferably, the carrier, excipient and diluent include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil and the like. Preferably, the medicament is in the form of suspension, emulsion, granule, spray, injection, transdermal absorbent, dosage form suitable for transfection, tablet, powder, granule or capsule. In a third aspect of the invention there is provided a pharmaceutical composition comprising an antifungal agent as described in the second aspect. The invention has the beneficial effects that: according to the invention, trace broth dilution method, dynamic time-sterilization curve, hypha growth and large wax moth animal test prove that the